An open-label, single-dose, two-treatment, randomized, two-way crossover, safety, tolerance, and pharmacokinetic study of TR-701 [torezolid] in normal healthy adults in the fed and fasted state

Trial Profile

An open-label, single-dose, two-treatment, randomized, two-way crossover, safety, tolerance, and pharmacokinetic study of TR-701 [torezolid] in normal healthy adults in the fed and fasted state

Completed
Phase of Trial: Phase I

Latest Information Update: 04 May 2016

At a glance

  • Drugs Tedizolid (Primary)
  • Indications Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Vancomycin-resistant enterococcal infections
  • Focus Adverse reactions
  • Sponsors Trius Therapeutics
  • Most Recent Events

    • 12 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 17 May 2009 Results have been reported at the 19th European Congress of Clinical Microbiology and Infectious Diseases.
    • 26 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top